BlackRock Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

BlackRock Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.2M	Sell	34,710 -1,598	-4%	-$101K	﹤0.01%	1467
2016 Q3	$2.31M	Sell	36,308 -24,008	-40%	-$1.76M	﹤0.01%	1402
2016 Q2	$4.49M	Buy	60,316 +1,781	+3%	+$132K	﹤0.01%	1146
2016 Q1	$3.91M	Sell	58,535 -122	-0.2%	-$7.42K	﹤0.01%	1190
2015 Q4	$3.97M	Sell	58,657 -10,591	-15%	-$654K	﹤0.01%	1174
2015 Q3	$3.7M	Sell	69,248 -2,898	-4%	-$176K	﹤0.01%	1189
2015 Q2	$4.54M	Sell	72,146 -29,051	-29%	-$1.59M	﹤0.01%	1022
2015 Q1	$4.87M	Sell	101,197 -14,700	-13%	-$563K	0.01%	980
2014 Q4	$3.85M	Buy	115,897 +3,535	+3%	+$115K	﹤0.01%	1039
2014 Q3	$3.29M	Sell	112,362 -189	-0.2%	-$6.27K	﹤0.01%	1059
2014 Q2	$4.37M	Buy	112,551 +61,528	+121%	+$2.5M	﹤0.01%	1003
2014 Q1	$2.14M	Buy	51,023 +25,833	+103%	+$1.08M	﹤0.01%	1162
2013 Q4	$827K	Buy	25,190 +2,187	+10%	+$71.3K	﹤0.01%	1649
2013 Q3	$621K	Sell	23,003 -26,727	-54%	-$752K	﹤0.01%	1747
2013 Q2	$1.16M	Buy	+49,730	New	+$894K	﹤0.01%	1316

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock Advisors's LGND Position: Q4 2016 in Review

BlackRock Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 4.4% in Q4 2016, selling an estimated $101K and leaving 34,710 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

BlackRock Advisors first reported a position in LGND in Q2 2013 and has held it in 15 quarters since. The position peaked at $4.87M in Q1 2015. 269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

BlackRock Advisors held 34,710 shares of Ligand Pharmaceuticals worth $2.2M as of Q4 2016.
BlackRock Advisors sold 1,598 Ligand Pharmaceuticals shares in Q4 2016, an estimated $101K.
Ligand Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1467 holding.
BlackRock Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Ligand Pharmaceuticals position peaked at $4.87M in Q1 2015.
269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.